Patients with any of the three subtypes of the myeloproliferative neoplasms (MPNs) can progress to a form of acute myeloid leukemia (AML) that is very aggressive and responds poorly to therapy. Here, we will to identify the pathways that govern the progression of the MPNs to AML. To accomplish this we will perform a CRISPR screen to identify genes whose dysregulation cause Jak2V617F to give rise to AML in vivo and characterize these pathways with the goal of developing novel therapies.
|Effective start/end date||10/1/15 → 9/30/18|
- Leukemia & Lymphoma Society (GN# 9001-16)